MktsMarkets

Cellectar Biosciences, Inc.
NASDAQ: CLRBKey statistics
CLRB News
Stories mentioning CLRB from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 3,007 | 3,159 | 2,523 | 2,390 | 3,427 | 6,210 | 5,493 | 7,345 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (5,794) | (5,690) | (4,851) | (6,038) | (6,401) | (12,745) | (13,328) | (13,704) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (5,654) | (5,295) | (4,444) | (5,448) | (6,604) | (2,355) | (14,665) | (919.00) |
| Earnings Per Share (Basic) | (1.33) | (2.03) | (1.41) | (3.39) | (4.30) | (1.93) | (11.18) | (0.77) |
| Earnings Per Share (Diluted) | (1.33) | (2.03) | (1.41) | (3.39) | (4.30) | (1.90) | (12.13) | (5.43) |
| Weighted Average Shares Outstanding (Basic) | 4,240 | 2,608 | 3,162 | 1,609 | 1,536 | 1,221 | 1,311 | 1,194 |
| Weighted Average Shares Outstanding (Diluted) | 4,240 | 2,608 | 3,162 | 1,609 | 1,536 | 1,238 | 1,326 | 1,248 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CLRB
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a stock listed on the Nasdaq Stock Market under the ticker symbol CLRB. It last traded at $1.14 (Nov 13, 2026, 4:00 PM ET), down 1.7% on the day. That gives Cellectar Biosciences a market capitalisation of $11.4M.
Over the past 52 weeks CLRB has traded between $1.11 and $4.70.
For the quarter ended Mar 31, 2026 it reported a net loss of $5.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$5.7M |
| Dec 31, 2025 | — | -$5.3M |
| Sep 30, 2025 | — | -$4.4M |
| Jun 30, 2025 | — | -$5.4M |
From Cellectar Biosciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…